Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

Professor Sally Ann Cryan


Professor Sally Ann Cryan BSc (Pharm), PhD, MPSI
Associate Professor in Pharmaceutics / Research Convenor for School of Pharmacy [2010-2014]
Tel: 01 402 2741

Sally Ann Cryan graduated with a BSc. (Pharmacy) from Trinity College, Dublin (TCD), subsequently carried out PhD research in pharmaceutical biotechnology in TCD and went on to work as a Post-doctoral Research Fellow in RCSI. In 2003, she was awarded a Fulbright Scholarship to carry out research the Schools of Pharmacy and Medicine, University of North Carolina at Chapel Hill. In 2004 she was appointed as Lecturer in Pharmaceutics in the School of Pharmacy, Senior Lecturer in October 2008 and promoted to Associate Professor in Pharmaceutics in 2013. She is a founding member and PI of the SFI-funded Irish Drug Delivery Network (IDDN) (, a PI in the RCSI Tissue Engineering Research Group (TERG) and was recently appointed as a PI in the Trinity Centre for Bioengineering. Her research group collaborates extensively with clinical, industrial & biomedical research groups and is currently part of two EU FP7 consortia AMCARE ( (Co-ordinator:Dr. G Duffy) and NeoGel ( (Co-ordinator Dr. A Heise, DCU) for Bioengineering.

Professional Committees
Member of the HRB PhD Scholars Programme in Therapeutics and Diagnostics for Human Disease Working Committee (2007-present).
Member of AAPS Books Editorial Advisory Group (2007-2008).
Member of Scientific Advisory Board of Ludwig Boltzmann Institute for Lung Vascular Research(2012- present).

Research Interests
Delivery of biopharmaceuticals including proteins and genes
Non-viral gene delivery systems for transfection of a range of cell types including cancer, immune, epithelial and stem cells
Liposome and peptide-based drug delivery systems
Nanoparticle and microparticle drug delivery systems
Respiratory drug delivery
Bioengineering of bioresponsive drug delivery systems
Development of in vitro and in vivo models for the assessment of novel drug delivery platforms
Novel treatment strategies for inflammatory lung disease and respiratory infections, including tuberculosis

O'Connor G, Gleeson LE, Fagan-Murphy A, Cryan SA, O'Sullivan MP, Keane J. Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv Drug Deliv Rev. 2016 Jul 1;102:33-54. doi: 10.1016/j.addr.2016.04.024. Epub 2016 May 2

O'Leary C, Cavanagh B, Unger RE, Kirkpatrick CJ, O'Dea S, O'Brien FJ, Cryan SA. The development of a tissue-engineered tracheobronchial epithelial model using a bilayered collagen-hyaluronate scaffold. Biomaterials. 2016 Apr;85:111-27. doi: 10.1016/j.biomaterials.2016.01.065. Epub 2016 Feb 1.

Lawlor C, O'Connor G, O'Leary S, Gallagher PJ, Cryan SA, Keane J, O'Sullivan MP. Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NF?B and Autophagy Dependent Bacillary Killing. PLoS One. 2016 Feb 19;11(2):e0149167. doi: 10.1371/journal.pone.0149167. eCollection 2016.

Raftery RM, Walsh DP, Castaño IM, Heise A, Duffy GP, Cryan SA, O'Brien FJ. Delivering Nucleic-Acid Based Nanomedicines on Biomaterial Scaffolds for Orthopedic Tissue Repair: Challenges, Progress and Future Perspectives. Adv Mater. 2016 Feb 3. doi: 10.1002/adma.201505088. [Epub ahead of print].

O'Neill HS, Gallagher LB, O'Sullivan J, Whyte W, Curley C, Dolan E, Hameed A, O'Dwyer J, Payne C, O'Reilly D, Ruiz-Hernandez E, Roche ET, O'Brien FJ, Cryan SA, Kelly H, Murphy B, Duffy GP. Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives. Adv Mater. 2016 Feb 3. doi: 10.1002/adma.201505349. [Epub ahead of print].

Byrne M, Murphy R, Kapetanakis A, Ramsey J, Cryan SA, Heise A. Star-Shaped Polypeptides: Synthesis and Opportunities for Delivery of Therapeutics. Macromol Rapid Commun. 2015 Sep 17. doi: 10.1002/marc.201500300. [Epub ahead of print].

O'Leary C, Gilbert JL, O'Dea S, O'Brien FJ, Cryan SA. Respiratory Tissue Engineering: Current Status and Opportunities for the Future. Tissue Eng Part B Rev. 2015 Aug;21(4):323-44. doi: 10.1089/ten.TEB.2014.0525. Epub 2015 Mar 3.

Brayden DJ, Cryan SA, Dawson KA, O'Brien PJ, Simpson JC. High-content analysis for drug delivery and nanoparticle applications. Drug Discov Today. 2015 Aug;20(8):942-57. doi: 10.1016/j.drudis.2015.04.001. Epub 2015 Apr 20.

Raftery RM, Tierney EG, Curtin CM, Cryan SA, O'Brien FJ. Development of a gene-activated scaffold platform for tissue engineering applications using chitosan-pDNA nanoparticles on collagen-based scaffolds. J Control Release. 2015 Jul 28;210:84-94. doi: 10.1016/j.jconrel.2015.05.005. Epub 2015 May 15.

Quinlan E, López-Noriega A, Thompson EM, Hibbitts A, Cryan SA, O'Brien FJ. Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. J Tissue Eng Regen Med. 2015 Mar 18. doi: 10.1002/term.2013. [Epub ahead of print].

Quinlan E, López-Noriega A, Thompson E, Kelly HM, Cryan SA, O'Brien FJ. Development of collagen-hydroxyapatite scaffolds incorporating PLGA and alginate microparticles for the controlled delivery of rhBMP-2 for bone tissue engineering. J Control Release. 2015 Jan 28;198:71-9. doi: 10.1016/j.jconrel.2014.11.021. Epub 2014 Dec 4.

Curtin CM, Tierney EG, McSorley K, Cryan SA, Duffy GP, O'Brien FJ. Combinatorial gene therapy accelerates bone regeneration: non-viral dual delivery of VEGF and BMP2 in a collagen-nanohydroxyapatite scaffold. Adv Healthc Mater. 2015 Jan 28;4(2):223-7. doi: 10.1002/adhm.201400397. Epub 2014 Aug 13.

Kelly C, Lawlor C, Burke C, Barlow JW, Ramsey JM, Jefferies C, Cryan SA. High-throughput methods for screening liposome-macrophage cell interaction. J Liposome Res. 2014 Dec 30:1-11. [Epub ahead of print].

Kelly C, Yadav AB, Lawlor C, Nolan K, O'Dwyer J, Greene CM, McElvaney NG, Sivadas N, Ramsey JM, Cryan SA. Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFa gene silencing in macrophages. Mol Pharm. 2014 Nov 3;11(11):4270-9. doi: 10.1021/mp500473d. Epub 2014 Oct 13. pMID: 25243784

McKiernan PJ, Molloy K, Cryan SA, McElvaney NG, Greene CM Long noncoding RNA are aberrantly expressed in vivo in the cystic fibrosis bronchial epithelium. Int J Biochem Cell Biol. 2014 Jul;52:184-91. doi: 10.1016/j.biocel.2014.02.022. Epub 2014 Mar 12. PMID: 24631641

Wynne C, Lazzari E, Smith S, McCarthy EM, Ní Gabhann J, Kallal LE, Higgs R, Greco A, Cryan SA, Biron CA, Jefferies CA. TRIM68 negatively regulates IFN-ß production by degrading TRK fused gene, a novel driver of IFN-ß downstream of anti-viral detection systems. PLoS One. 2014 Jul 7;9(7):e101503. doi: 10.1371/journal.pone.0101503. eCollection 2014.

McKiernan PJ, Cunningham O, Greene CM, Cryan SA.Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int J Nanomedicine. 2013;8:3907-15. doi: 10.2147/IJN.S47551. Epub 2013 Oct 11. PMID: 24143095.

Kelly C., Yadav AB, McKiernan PJ, Greene CM, Cryan SA. RNAi in respiratory diseases in "Advanced Delivery and Therapeutic Applications of RNAi. Kun Cheng and Ram I. Mahato (Eds), John Wiley & Sons Ltd, Chichester. Copyright (2013) John Wiley & Sons Ltd.

Tierney EG, McSorley K, Hastings CL, Cryan SA, O'Brien T, Murphy MJ, Barry FP, O'Brien FJ, Duffy GP. High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix. J Control Release. 2013 Feb 10;165(3):173-82.

Byrne M,Thornton PD, Cryan SA, Heise A. Star polypeptides by NCA polymerisation from dendritic initiators: synthesis and enzyme controlled payload release Polym. Chem., 2012, 3, 2825-2831

Lawlor, C., O'Sullivan, M.P., Rice, B., Dillon, P., Gallagher, P.J., O'Leary, S., Shoyele, S., Keane, J., Cryan, S.A. ‘Therapeutic Aerosol Bioengineering of Targeted, Inhalable Microparticle Formulations to Treat Mycobacterium Tuberculosis (MTB).' Journal of Material Science: Materials in Medicine, 2012: 23(1), 89-98

Tierney EG, Duffy GP, Hibbitts AJ, Cryan SA, O'Brien FJ. The development of non-viral gene-activated matrices for bone regeneration using polyethyleneimine (PEI) and collagen-based scaffolds. J Control Release. 2012 Mar 10;158(2):304-112011 Nov 27.

Hassan T, McKiernan PJ, McElvaney NG, Cryan SA, Greene CM. Therapeutic modulation of microRNA for the treatment of pro-inflammatory lung diseases. Expert Review of Anti-infective therapy. March 2012, Vol. 10, No. 3, Pages 359-368.

Lawlor, C., O'Sullivan, M.P., Sividas, N., O'Leary, S., Gallagher, P.J., Keane, J., Cryan, S.A. ‘The Application of High Content Analysis (HCA) in the Study of Targeted Particulate Delivery Systems for Intracellular Drug Delivery to Alveolar Macrophages.' Molecular Pharmaceutics. 2011: 8(4), 1100-12.

Hibbitts A, Lieggi N, McCabe O, Thomas W, Barlow J, Fiona O'Brien F, Cryan SA. Screening of siRNA Nanoparticles for Delivery to Airway Epithelial Cells Using High Content Analysis. Therapeutic Delivery, 2011 Vol. 2, No. 8, Pg987-999.

Gibbons, A., Padilla-Carlin, D., Kelly, C., Hickey, A., Taggart, C., McElvaney, N.G., Cryan, S.A. ‘The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model.' Pharmaceutical Research. 2011: 28(9), 2233-45.

Desgranges S, Prieult F, Daly A, Lydon J, Brennan M, Rai D, Subasinghage A, Hewage CM, Cryan SA, Greene CM, McElvaney NG, Smyth TP, Fitzgerald-Hughes D, Humphreys H, Devocelle M. In Vitro Activities against Cystic Fibrosis Pathogens of Synthetic Host Defence Propeptides Processed by Neutrophil Elastase. In Press. Antimicrobial Agents and Chemotherapy

Kelly C, Jefferies C and Cryan SA. Targeted Liposomal Drug Delivery to Monocytes and Macrophages. Journal of Drug Delivery, Volume 2011 (2011), Article ID 727241

Lawlor C, Kelly C, O'Leary S, O'Suliivan MP, Gallagher P, Keane J, Cryan SA. Cellular Targeting And Trafficking Of Drug Delivery Systems For The Prevention And Treatment of MTb. Tuberculosis 2011, 91 (1) 93-97 PMID: 2123771

Sivadas N, Cryan SA. Inhalable, bioresponsive microparticles for targeted drug delivery in the lungs. Journal of Pharmacy & Pharmacology. 2011, 63(3) 369-375

Sunday S, Sivadas N, Cryan SA. The Effects of Excipients and Particle Engineering on the Biophysical Stability and Aerosol Performance of Parathyroid Hormone (1-34) Prepared as a Dry Powder for Inhalation. AAPSPharmSciTech, 2011 DOI: 10.1208/S12249-011-9585-2, PMID: 21271316

Gibbons A, McElvaney NG, Cryan SA. A Dry Powder Formulation of Liposome-Encapsulated Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) for Inhalation: Preparation and Characterisation. AAPS PharmSciTech 2010, Vol. 11(3) 1411-1421. PMID: 2083907.

Gibbons AM, McElvaney NG, Taggart CC, Cryan SA. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul. 2009 Sep;26(6):513-22.

Sivadas N, O' Rourke D, Tobin A, Buckley V, Ramtoola Z, Kelly JK, Hickey AJ, Cryan, SA. A comparative study of a range of polymeric microspheres as potential carriers for inhalation. International Journal of Pharmaceutics. 2008, 358 (1-2), 159-167.

Durcan N, Cryan SA. Inhalable siRNA, Molecular Pharmaceutics, 2008, 5(4), 559-66

Cryan SA, Sivadas NKS, Garcia-Contreras L. In Vivo Animal models for Drug Delivery Across the Lung Mucosal Barrier, Advanced Drug Delivery Reviews, Adv Drug Deliv Rev. 2007 Sep 30;59(11):1133-51.

Cryan SA, Moran PJ. The Science Behind Biopharmaceuticals, Irish Pharmacy Journal, 2007, (5) 85

Cryan SA, Devocelle M, Moran P, Hickey AJ, Kelly JG. Increased intracellular targeting to airway cells using octa-arginine coated liposomes - in vitro assessment of their suitability for inhalation. Molecular Pharmaceutics, 2005, Mar-Apr 3(2):104-2.

Taggart C, Cryan SA, Weldon S, Gibbons A, Greene CM, O'Neill SJ, McElvaney NG. Secretory Leucoprotease Inhibitor binds to NF-kB Binding Sites in Monocytes and Inhibits p65 Binding. J Exp Med 2005, 202, No. 12, 1659-68.

Cryan SA, Inhalers-The Next Generation, Irish Pharmacy Journal, 2005, 83(12) 501-503

Cryan SACarrier-based Strategies for Targeting Protein and Peptide Drugs to the Lungs.Journal of AAPS, 2005, 07(01), E20-E41

Moran, P, Cryan, SA, Foley, V, Devocelle, M and Kelly, J. Use of Octa-arginine for Intracellular Delivery to Airway Cells. in Respiratory Drug Delivery IX Dalby, R, Byron, P, Peart, J, Suman, J and Farr, S, Editors. River Grove: Davis Healthcare International Publishing p. 665-668, 2004.

Pharmacy's Role in the Genomic Revolution: Gene Therapy. Cryan, SA, Irish Pharmacy Journal, 2004, 82(2) 76-82,.

Cationic Cyclodextrin Amphiphiles as Gene Delivery Vectors. Cryan, SA, Donohue, R, Ravoo, B, Darcy, R and CM O'Driscoll. Journal of Drug Delivery Science and Technology, 2004, 14(1) 57-62.

Cell Transfection with Polycationic Cyclodextrin Vectors. Cryan, SA, Holohan, A, Donoghue R, Darcy, R, and CM O'Driscoll European Journal of Pharmaceutical Sciences, 2004, 21(5) 625-633,.

Mechanistic studies on nonviral gene delivery to the intestine using in vitro differentiated cell culture models and an in vivo rat intestinal loop.Cryan, SA, O'Driscoll, CM Pharm Res. 2003, 20(4):569-75.